A recent study suggests that patients who discontinue blockbuster slimming jabs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who halt traditional lifestyle plans.
Published data in a major medical journal demonstrates that while overweight individuals frequently drop substantial amounts of their total mass while using the jabs, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"People using these treatments need to be aware of the risk of quick rebound weight gain when the medication ends," cautioned researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to pre-treatment mass within about one and a half years.
Weighing Approaches
The study, which looked at dozens of trials involving over 9,000 of patients, compared the outcomes of these new drugs with conventional dieting.
Scientists point out that people who lose weight through diet and exercise generally see a slower creep back—perhaps 0.1 kg a month—once they finish.
Explaining the Rapid Rebound
Doctors propose the mechanism of the drugs is key to understanding the heightened rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than normal could lead to the system to produce less of its own natural hormone, and could lessen responsiveness to its actions," explained Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating much more probable."
An Ongoing Issue?
The NHS advise the jabs for individuals with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, considering the significant potential of weight regain, the therapy might need to be life-long.
This perspective is reinforced by drug manufacturers, who say that the results "underscore the long-term character of excess weight," akin to managing conditions like diabetes.
User Testimonies
People who have come off the medication explain a intense return of cravings.
"I experienced a switch activating and I was suddenly ravenous," recalled a patient.
This challenge is exacerbated if users have not developed permanent lifestyle or habit modifications during treatment.
Growing Use
Recent estimates suggest that a significant number of people in the UK have tried weight-loss jabs in the past year, with interest continuing to grow.
- Adoption is greater among females than men.
- The middle-aged age group shows the highest usage rates.
- Many obtain the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are potent tools for weight loss, they are not a permanent fix and maintained weight loss relies on combined lifestyle support.
